Our partnershipsportfolio

Financial support, risk mitigation and validation

Partner Collaboration Financial terms

Sanofi
sanofi.com

Global license agreement to develop and commercialize lixisenatide (Lyxumia®) and any combination product, which include lixisenatide

Financing: All covered by Sanofi

Milestones to Zealand: USD 275 million, of which USD 160 million is outstanding.

Royalties to Zealand: Tiered, low double-digit percentages on sales of Lyxumia® and fixed, low-double digit percentage on sales of combination products, which include lixisenatide.

Helsinn Healthcare 
helsinn.com

Worldwide exclusive agreement on the development and commercialization of elsiglutide within a specific field in cancer supportive care

Financing: All covered by Helsinn

Milestones to Zealand: Up to EUR 140 million, of which
EUR 14 million has been received.

Royalties to Zealand: High single digit percentages of Helsinn’s global sales of elsiglutide. Zealand has an option to obtain commercial rights to elsiglutide in the Nordic countries.

Abbvie 
abbvie.com

License agreement on
ZP1480 (ABT-719)

Financing: All covered by AbbVie

Royalties to Zealand: Low single digit percentage on global sales of the product.

Boehringer Ingelheim
boehringer-Ingelheim.com

Global license and collaboration agreement to develop and commercialize glucagon/GLP-1 dual acting agonists for the treatment of Type 2 diabetes and/or obesity

Financing: All covered by Boehringer Ingelheim

Milestones to Zealand: Up to EUR 376 million, of which EUR 365 million remaining, in total for potential development, regulatory and commercial events relating to the lead candidate – additional, potential milestones for other products from the collaboration.

Royalties to Zealand: Ranging from high single to low double digits on global sales of products from the collaboration.

Eli Lilly
lilly.com

Collaboration agreement to design and develop novel therapeutic peptides for Type 2 diabetes and obesity 

Financing: The companies will share the funding, risk and reward of the program.